Modex Solid Tumor Trial

The same Louise Chen who was referenced in a Yahoo article on Nov 9 2017: "Opko Health Inc. (NASDAQ:OPK) delivered a sore sight to the Street yesterday with a sharp third quarter miss in earnings that has sent investors scrambling away in the aftermath. However, Cantor analyst Louise Chen makes a confident case for the drug maker's "underappreciated" earnings potential."

On Nov 8 2017, Opko closed at $6.45 (yup you read that right). After the close, the OPKO bed had some stains from, well it wasn't from a magic workout. The company posted $246 million in revenue, and a $43 million loss, for a loss of $0.08/share. Funny how seven years later, we have 1) less cash, 2) more shares (697 million vs 559 million), 3) about $64 million less in quarterly revenue, 4) more than twice the long term debt, and 5) bigger quarterly losses on both an absolute and an EPS basis (despite a much higher share count).

This is a pretty damn good set of data that indicates the profound ineptitude of the imbecilic Phil Frost. Just look at the numbers! Even Louise Chen moved on from us, not long after calling us 'under appreciated.'

So I don't place too much value on Louise's recommendations. But both Josh Brown of Ritholz (whom I respect a lot.....see him regularly on The Halftime Report at noon on CNBC) and a friend who is one of the best traders I've ever known (interestingly, he was a convert arb guy when I met him), have purchased PFE recently. And I respect their opinions WAY more than those of Louise.

Back to Frost, if the numbers above aren't evidence enough to convince that the guy has been a disaster, and a greedy stubborn fool as well, then nothing will. The real criminality rests with a guy like Rubin, who may be one of the few who could've convinced Phil to step aside as CEO. But he was too compromised by his salary to do what was right. And now? It may be too late.....